Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Filling the gaps in COPD: the TRIBUTE study

Chronic obstructive pulmonary disease (COPD) is a major public health problem because of its high prevalence (about 10% of the adult population), rising incidence (COPD is predicted to be the third global cause of death by 2020), and high associated personal, social, and economic costs.1 Regular physical activity, appropriate vaccination, and avoiding toxic exposures (eg, tobacco smoking) are important non-pharmacological approaches for the management of patients with COPD.1 Meanwhile, pharmacological treatment for COPD is fundamentally based on the use of inhaled drugs: long-acting bronchodilators (long-acting antimuscarinic agents, long-acting β2 agonists, or both), with or without inhaled corticosteroids.